Neuphoria Therapeutics (NASDAQ:NEUP) Shares Up 17.7% – Should You Buy?

Shares of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) rose 17.7% during trading on Thursday . The company traded as high as $4.20 and last traded at $3.92. Approximately 7,610,379 shares traded hands during mid-day trading, an increase of 8,538% from the average daily volume of 88,104 shares. The stock had previously closed at $3.33.

Analyst Upgrades and Downgrades

NEUP has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Trading Up 17.7%

The stock has a market capitalization of $21.17 million, a P/E ratio of -0.35 and a beta of 0.74. The stock’s 50 day simple moving average is $4.31 and its 200 day simple moving average is $4.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.47. On average, sell-side analysts expect that Neuphoria Therapeutics Inc. will post -4.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Neuphoria Therapeutics

A number of hedge funds have recently bought and sold shares of NEUP. AdvisorShares Investments LLC increased its holdings in Neuphoria Therapeutics by 15.8% in the first quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock valued at $632,000 after buying an additional 21,173 shares during the last quarter. XTX Topco Ltd bought a new position in Neuphoria Therapeutics during the 4th quarter worth approximately $47,000. Ikarian Capital LLC bought a new position in Neuphoria Therapeutics during the 4th quarter worth approximately $184,000. Boothbay Fund Management LLC acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $54,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $57,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.